NK Biocell Sdn. Bhd. has successfully transferred NK cell immune cell therapy “MYJ1633” technology from Korea-based Biotechnology Immunis Bio Co., Ltd. on March 2021. Immunis Bio Co., Ltd. exclusively supplies core solutions and raw materials for immune cell therapy manufacturing in NK Biocell Sdn. Bhd.

“MYJ1633” is an autologous Natural Killer (NK) immune cell therapy that can be applied to blood cancer and solid cancer. It has been commercialized in Japan and Vietnam and is being administered to cancer patients. “MYJ1633” is cultivated with excellent technology, it is effective in anti-aging, as well as cancer and autoimmune disease treatment. In addition, it is perfectly safe without worrying about genetic modification and side effects.

CEO of Immunis Bio Co., Ltd., Kang Jung-hwa said, “It is meaningful that our cell therapy products, which are bearing fruit in the immune cell therapy market, are pioneering new markets following Japan and Vietnam. I will try to get it, ” he said.

NK Biocell Sdn. Bhd. said, “It is estimated that 85,000 of the current Malaysian population of about 32 million are registered as new cancer patients every year. It is the highest at about 28%, so it is expected to have high growth potential in the future.”

Additionally, NK Biocell Sdn. Bhd. said, “Through the use of Immunis Bio’s cell therapy technology, it is expected to strengthen competitiveness in anti-aging and beauty related areas for existing patients, and to expand partner hospitals nationwide. It will be an opportunity,” he said.

Click here for more information: http://immunisbio.co.kr/page/comm/press/view.php?board_number=29